Background: Myeloid-derived suppressor cells (MDSCs) play a crucial role in the tumor microenvironment (TME) of cervical cancer (CC), yet the mechanisms underlying their reprogramming remain poorly understood. Methods: To explore the immune microenvironment change in CC, we applied TCGA-CC immune microenvironment infiltration estimation analysis via Timer 2.0 online datasets. To generate tumor-conditioned MDSCs, the culture medium of MDSCs was supplemented with supernatants from the murine CC cell lines U14 and TC1, respectively. CCK8 assays, transwell migration experiments and qPCR were executed to test the proliferation, migration and iNOS expression. We then conducted proteomics and metabolomics analyses of tumor-conditioned MDSCs. Results: The tumor immune microenvironment analysis identified MDSCs as key components, predicting poor prognosis in CC. Tumor-conditioned MDSCs presented higher proliferation, migration and iNOS expression. Proteomics and metabolomics analyses showed significant changes in lipid metabolism, especially sphingolipid metabolism. Specifically, the Kng1–sphingosine 1-phosphate axis was identified as a central protein–metabolite regulatory node. Gain- and loss-of-function experiments confirmed that KNG1 modulates multiple cellular processes including proliferation, migration, iNOS expression, and sphingosine 1-phosphate production. Conclusion: Our findings uncover sphingolipid metabolic reprogramming as a key mechanism in MDSCs-mediated immune suppression, and propose the Kng1–sphingosine 1-phosphate network as a potential therapeutic target for CC treatment.
Migraine is a prevalent and debilitating neurological disorder with poorly understood neural mechanisms. Here, we characterize a hypothalamic‐trigeminal pathway involved in the regulation of migraine‐like allodynia. Using a combination of monosynaptic circuit, fiber photometry‐based calcium imaging, and behavioral assays in a nitroglycerin (NTG)‐induced murine model, we observed hyperactivity in corticotropin‐releasing factor (CRF)‐expressing neurons within the hypothalamic paraventricular nucleus (PVN). Activation or inhibition of PVN CRF neurons mimicked or blocked migraine‐like allodynia, respectively. These PVN CRF neurons modulated migraine‐like allodynia by exciting glutamatergic neurons in the spinal trigeminal nucleus caudalis (SP5C). Furthermore, employing a CRF neurotransmitter fluorescent sensor, neuropharmacology, and electrophysiological recordings, we revealed that PVN CRF neurons excessively release CRF neuropeptides onto SP5C Glu neurons during migraine‐like conditions. This led to hyperactivation of corticotropin‐releasing factor receptor type 2 (CRFR2), but not type 1 (CRFR1), resulting in hyperalgesia. Blockade of CRFR2 within the SP5C significantly alleviated migraine‐like allodynia. Complementing these findings, clinical functional magnetic resonance imaging (fMRI) of migraine patients indicated structural and functional alterations in PVN and SP5C regions associated with this pathway. Collectively, our results uncover a previously unappreciated PVN CRF ‐SP5C Glu pathway in migraine‐like allodynia, providing novel insights into the neurobiology of migraine and identifying potential therapeutic targets.
9 February 2026 in Proceedings of the National Academy of Sciences
COVID-19 has been associated with high prevalences of retinal diseases in humans. However, cellular and molecular mechanisms that underlie the COVID-19-associated retinopathy remains unknown. Here, we deployed a mouse COVID-19 model to investigate the causative link between SARS-CoV-2 infection and retinopathy development. Our data showed that COVID-19-induced pulmonary hypoxia triggered systemic hypoxia and markedly augmented VEGF expression levels in the retina and plasma. High VEGF levels altered vascular structures and functions in the retina, resulting in neovascularization, vascular disorganization, and increased leakiness. We deployed a terminology of coviretinopathy to accurately describe these COVID-19-induced pathological changes in the retina. Consequently, blocking VEGF by a specific neutralizing antibody (VEGF blockade) completely ablated the COVID-19-associated vascular changes in the retina. Together, these findings provide mechanistic insights into the COVID-19-associated retinopathy and propose a therapeutic paradigm for effective treatment of coviretinopathy.